BRISTOL MYERS SQUIBB

Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery as the ninth member, gaining access to a comprehensive clinical genomic database containing 250,000 whole-genomes to accelerate RNA interference therapeutic development.

AstraZeneca's subcutaneous formulation of Saphnelo (anifrolumab) demonstrated statistically significant and clinically meaningful reduction in disease activity compared to placebo in the Phase III TULIP-SC trial for systemic lupus erythematosus.

Biocartis has received FDA Premarket Approval for the Idylla™ CDx MSI Test, marking the first fully automated, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients.

CatalYm appointed four experienced executives to accelerate visugromab's progression into late-stage clinical development following promising Phase 2a results.

BioNTech and Bristol Myers Squibb's investigational bispecific antibody pumitamig (BNT327) demonstrated a 76.3% confirmed objective response rate in a Phase II trial for extensive-stage small cell lung cancer.

BioNTech and Bristol Myers Squibb presented interim Phase 2 data showing pumitamig plus chemotherapy achieved a 76.3% confirmed objective response rate and 100% disease control rate in extensive-stage small cell lung cancer patients.

CHARM Therapeutics has appointed Dr. Erkut Bahceci as Chief Medical Officer following an $80 million Series B financing to advance its next-generation menin inhibitor for acute myeloid leukemia.

Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Netherlands-based Synthon BV to commercialize generic Ozanimod capsules for multiple sclerosis treatment in the US market.

The phase III ODYSSEY-HCM trial involving 580 patients showed mavacamten did not significantly improve symptoms or exercise capacity compared to placebo in non-obstructive hypertrophic cardiomyopathy patients at 48 weeks.

I-Mab appointed three seasoned biotech executives to key leadership positions, including Dr. Robert Lenz and Ms. Xin Liu to the Board of Directors and Dr. Ken Takeshita to the Scientific Advisory Board.